Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 1803

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus


Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

Kuldeep Dhama et al. Front Immunol.


Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola virus disease (EVD) (formerly named Ebola hemorrhagic fever). This is a severe, often fatal illness with mortality rates varying from 50 to 90% in humans. Although the virus and associated disease has been recognized since 1976, it was only when the recent outbreak of EBOV in 2014-2016 highlighted the danger and global impact of this virus, necessitating the need for coming up with the effective vaccines and drugs to counter its pandemic threat. Albeit no commercial vaccine is available so far against EBOV, a few vaccine candidates are under evaluation and clinical trials to assess their prophylactic efficacy. These include recombinant viral vector (recombinant vesicular stomatitis virus vector, chimpanzee adenovirus type 3-vector, and modified vaccinia Ankara virus), Ebola virus-like particles, virus-like replicon particles, DNA, and plant-based vaccines. Due to improvement in the field of genomics and proteomics, epitope-targeted vaccines have gained top priority. Correspondingly, several therapies have also been developed, including immunoglobulins against specific viral structures small cell-penetrating antibody fragments that target intracellular EBOV proteins. Small interfering RNAs and oligomer-mediated inhibition have also been verified for EVD treatment. Other treatment options include viral entry inhibitors, transfusion of convalescent blood/serum, neutralizing antibodies, and gene expression inhibitors. Repurposed drugs, which have proven safety profiles, can be adapted after high-throughput screening for efficacy and potency for EVD treatment. Herbal and other natural products are also being explored for EVD treatment. Further studies to better understand the pathogenesis and antigenic structures of the virus can help in developing an effective vaccine and identifying appropriate antiviral targets. This review presents the recent advances in designing and developing vaccines, drugs, and therapies to counter the EBOV threat.

Keywords: Ebola virus; Ebola virus disease; drugs; prophylactics; therapeutics; treatment; vaccines.


Figure 1
Figure 1
Various vaccine platforms under progress for the development of a successful Ebola virus (EBOV) vaccine. Platforms like inactivated vaccine, DNA vaccine, virus-like particles, virus-like replicon particles (VRPs), plant-based vaccine, and recombinant viral-vectored vaccines are available.
Figure 2
Figure 2
Different therapeutic agents and drugs available for the treatment of Ebola virus disease (EVD). Some agents block the viral entry, some block the RNA polymerase, while some inhibit gene expression. Neutralizing antibodies and mAbs have shown the potential to effectively inhibit Ebola virus (EBOV).

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Vogel WH, Viale PH. What you need to know about the Ebola virus. J Adv Pract Oncol (2014) 5(6):471–3. - PMC - PubMed
    1. Dhama K, Malik YS, Malik SV, Singh RK. Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives. J Infect Dev Ctries (2015) 9:441–55.10.3855/jidc.6197 - DOI - PubMed
    1. Singh RK, Dhama K, Malik YS, Ramakrishnan MA, Karthik K, Khandia R, et al. Ebola virus – epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans – an update on its 40 year’s journey. Vet Q (2017) 37(1):98–135.10.1080/01652176.2017.1309474 - DOI - PubMed
    1. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez J-P, Muyembe-Tamfum J-J, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo. Vector Borne Zoonotic Dis (2007) 9:6.10.1089/vbz.2008.0167 - DOI - PubMed
    1. Judson SD, Fischer R, Judson A, Munster VJ. Ecological contexts of index cases and spill over events of different ebolaviruses. PLoS Pathog (2016) 12(8):e1005780.10.1371/journal.ppat.1005780 - DOI - PMC - PubMed